文献速递消化道肿瘤放疗中枢神经肿瘤放疗姑息放疗与转移瘤

胃肠道肿瘤脑转移分级预后评估(GI-GPA)的验证

Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA).
PubMed 文献 · Radiat Oncol · 2020-02-13

本研究回顾性纳入92例德国和挪威的胃肠道肿瘤脑转移患者,均接受脑放疗。GI-GPA评分将患者分为4个预后层,中位生存分别为2.3、4.4、9.4和12.7个月(p=0.0001),验证了GI-GPA在独立数据集中的有效性,但各层总生存均短于原研究。

要点

  • GI-GPA评分可区分4个预后层,中位生存2.3至12.7个月(p=0.0001)。
  • 含手术切除者中位生存11.9个月,优于其他治疗者3.0个月(p=0.002)。
  • 加用全身治疗者中位生存8.5个月,优于未用者3.5个月(p=0.01)。

核心结论

  • GI-GPA在德国和挪威的独立数据集中验证有效,4个预后层中位生存分别为2.3、4.4、9.4和12.7个月(p=0.0001)。
  • 尽管各预后层总生存均短于Sperduto等原研究,GI-GPA仍能有效区分预后。

研究设计与样本

  • 回顾性研究,纳入92例德国和挪威的胃肠道肿瘤脑转移患者,均接受个体化治疗且始终包含脑放疗。
  • 收集年龄、颅外播散、脑转移数目、体能状态等变量,按Sperduto等所述计算GI-GPA评分。

主要发现

  • 总体中位生存为4个月,4个预后层中位生存分别为2.3、4.4、9.4和12.7个月(p=0.0001)。
  • 管理包含手术切除者中位生存11.9个月,其他治疗者为3.0个月(p=0.002)。
  • 加用全身治疗者中位生存8.5个月,未用者为3.5个月(p=0.01)。
  • 少数患者可实现超过5年的长期生存。

关键数值与推荐

  • GI-GPA评分按Sperduto等所述方法计算,将患者分为4个预后层。
  • 4个预后层中位生存分别为2.3、4.4、9.4和12.7个月(p=0.0001)。

临床怎么用

  • GI-GPA可用于胃肠道肿瘤脑转移患者的预后分层,辅助治疗决策。
  • 管理包含手术切除或加用全身治疗者中位生存更长,但为回顾性非随机比较。

局限性

  • 回顾性研究,样本量92例,治疗方式个体化且非随机。
  • 各预后层总生存均短于Sperduto等原研究,可能原因包括分子特征及脑转移和颅外治疗选择差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to validate a new prognostic model (GI-GPA) originally derived from a multi-center database (USA, Canada, Japan). PATIENTS AND METHODS: This retrospective study included 92 German and Norwegian patients treated with individualized approaches, always including brain radiotherapy. Information about age, extracranial spread, number of brain metastases, performance status and other variables was collected. The GI-GPA score was calculated as described by Sperduto et al. RESULTS: Median survival was 4 months. The corresponding figures for the 4 different prognostic strata were 2.3, 4.4, 9.4 and 12.7 months, respectively (p = 0.0001). Patients whose management included surgical resection had longer median survival than those who were treated with other approaches (median 11.9 versus 3.0 months, p = 0.002). Comparable results were seen for additional systemic therapy (median 8.5 versus 3.5 months, p = 0.01). CONCLUSION: These results confirm the validity of the GI-GPA in an independent dataset from a different geographical region, despite the fact that overall survival was shorter in all prognostic strata, compared to Sperduto et al. Potential explanations include differences in molecular tumor characteristics and treatment selection, both brain metastases-directed and extracranially. Long-term survival beyond 5 years is possible in a small minority of patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nieder C, Hintz M, Popp I, et al. Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA). Radiat Oncol. 2020. PMID: 32054485. doi:10.1186/s13014-020-1484-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。